Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
BERKELEY, Calif., May 02, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018, and host a conference call that day to review the results and provide a business update at 4:30pm ET/1:30pm PT.
To access the call, participants must dial (866) 548-4713 in the U.S. or (323) 794-2093 internationally, and use the conference ID 8635193. The live call will be webcast and can be accessed in the "Investors and Media" section of the company's website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event.
A replay of the conference call will be available for two weeks and can be accessed by dialing (844) 512-2921 in the U.S. or (412) 317-6671 internationally. The conference ID for the replay will be 8635193.
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, IR & Corporate Communications
510.665.7269
[email protected]
